Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors

Prostate

Volumn 36, Issue SUPPL. 8, 1998, Pages 43-51

  Cussenot, Olivier ^a,b,c   Villette, Jean Marie ^a   Cochand Priollet, Beatrix ^d   Berthon, Philippe ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT UNIVERSITAIRE DE FRANCE   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Chromogranin; Neuroendocrine; Neurosecretory system; Prostate cancer; Tumor marker

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CALCITONIN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; NEURON SPECIFIC ENOLASE; PANCREASTATIN; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN; SYNAPTOPHYSIN; TUMOR MARKER; ENOLASE; NEUROPEPTIDE; PANCREAS HORMONE; PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; TUMOR DIFFERENTIATION; BLOOD; CELL DIFFERENTIATION; DISEASE COURSE; NEUROSECRETION; PATHOLOGY; PROSTATE TUMOR; REVIEW;

CELL DIFFERENTIATION; CHROMOGRANIN A; CHROMOGRANINS; DISEASE PROGRESSION; HUMANS; MALE; NEUROPEPTIDES; NEUROSECRETORY SYSTEMS; PANCREATIC HORMONES; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 26844437741     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(1998)8+<43::AID-PROS8>3.0.CO;2-H     Document Type: Article

References (27)

1. Corti A, Gasparri A, Chen FX, Pelagi M, Brandazza A, Sidoli A, Siccardi AG: Characterisation of circulating chromogranin A in human cancer patients. Br J Cancer 1996; 73:924-932.
2. Stridsberg M, Oberg K, Qing L, Engstrom U, Lundquist G: Measurements of chromogranin A, chromogranin B (secretogranin 1), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumors and endocrine pancreatic tumors. J Endocrinol 1995;144:49-593.
3. di Sant'Agnese PA, Cockett ATK: The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 1994;152:1927-1931.
4. Pretl K: Zur frage der endokrin der menschlichen vorsteherdruse. Virchows Arch 1944;32:392-404.
5. Pearse AGE: The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-313.
6. di Sant'Agnese PA, de Mesy Jensen KL: Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987;18:849-856.
7. Abrahamsson PA, Alumets J, Wadstrom LB, Falkmer S, Grimelius L: Peptide hormones, serotonin, and other cell differentiation markers in benign hyperplasia and in carcinoma of the prostate. Prog Clin Biol Res 1987;243A:489-502.
8. Ohtake R: Four putative neuropeptides concentrations in the human urogenital tract. Comparison of the neuropeptides concentration between malignant and benign tissues. Nippon-Naibunpi-Gakkai-Zasshi 1989;65:1105-1115.
9. di Sant'Agnese PA, de Mesy Jensen KL, Ackroyd RK: Calcitonin, katacalcin and calcitonin gene-related peptide in the human prostate. An immunocytochemical and immunoelectron microscopic study. Arch Pathol Lab Med 1989;113,7:790-796.
10. di Sant'Agnese PA: Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-296.
11. Sasaki A, Yoshinaga K: Immunoreactive somatostatin in male reproductive system in humans. J Clin Endocrinol Metab 1989;68:996-999.
12. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-1720.
13. Pinski J, Shally AV, Halmos G, Szepeshazi K: Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PCS human prostatic cancer xenografts in nude mice. Int J Cancer 1993;55:963-967.
14. Cohen RJ, Glezerson G, Haffejee Z: Prostatic carcinoma: Histological and immuno-histological factors affecting prognosis. Br J Urol 1991;66:405-410.
15. Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994;74:1899-1903.
16. Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Duc A: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-1343.
17. Falkmer S, Askensten U, Nesland JM: Tumor pathology of the neuron-paraneuron system and its evolutionary background, with special attention to neuro-endocrine differentiation in prostate and mammary carcinomas. Arch Histol Cytol 1989;52(suppl):225-232.
18. Aprikian AG, Cordon-Cardo C, Fair W, Reuter VE: Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 1993;71:3952-3965.
19. Schally AV, Redding TW: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostatic cancer. Proc Natl Acad Sci USA 1987;84:7275-7279.
20. di Sant'Agnese PA, de Mesy Jensen KL: Endocrine-paracrine cells of the prostate and prostatic urethra: An ultrastructural study. Hum Pathol 1984;15:1034-1041.
21. di Sant'Agnese PA, de Mesy Jensen KL: Human prostatic endocrine-paracrine (APUD) cells: Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. Arch Pathol Lab Med 1985;109:607-612.
22. Cockett ATK, di Sant'Agnese PA, Gopinath P, Schoen S, Abrahamsson PA: Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 1993;42:512-517.
23. Bonkoff H, Stein U, Remberger K: Androgen receptor status in endocrine-Paracrine cell types of the normal, hyperplastic and neoplastic human prostate. Virchows Arch A Pathol Anat 1993;423:291-294.
24. Bonkoff H, Wernert N, Dhom G, Remberger K: Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic and neoplastic human prostate. Prostate 1991;19:91-98.
25. Noordzij MA, Van Der Kwast TH, Van Steenbrugge GJ, Hop WJC, Schröder MA: The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-258.
26. Segal N, Cohen F, Huffejee Z, Savage N: BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Med 1994;118:616-618.
27. Jiang S-X, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T: Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol 1996;148:837-846.